The ascendancy of Viagra and its influence on the drug landscape presents a intricate question for investors. While the early sales figures were remarkable, the exclusivity has expired, leading to a deluge of copycat alternatives that are chipping away at revenue. Moreover, the market is facing challenges related to aging trends and evolving health